Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PIK3CA E542K
i
Other names:
PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5290
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® Liquid CDx (21)
therascreen® PIK3CA RGQ PCR Kit (3)
FoundationOne® CDx (110)
FoundationOne® Liquid CDx (21)
therascreen® PIK3CA RGQ PCR Kit (3)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
PIK3CA E542K
HER2 Positive Breast Cancer
PIK3CA E542K
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
trastuzumab
Sensitive
:
B
trastuzumab
Sensitive: B - Late Trials
trastuzumab
Sensitive
:
B
PIK3CA E542K
HER2 Positive Breast Cancer
PIK3CA E542K
HER2 Positive Breast Cancer
PF-05212384 + trastuzumab-pkrb
Sensitive: C3 – Early Trials
PF-05212384 + trastuzumab-pkrb
Sensitive
:
C3
PF-05212384 + trastuzumab-pkrb
Sensitive: C3 – Early Trials
PF-05212384 + trastuzumab-pkrb
Sensitive
:
C3
PIK3CA E542K
Lung Adenocarcinoma
PIK3CA E542K
Lung Adenocarcinoma
crizotinib
Sensitive: C3 – Early Trials
crizotinib
Sensitive
:
C3
crizotinib
Sensitive: C3 – Early Trials
crizotinib
Sensitive
:
C3
PIK3CA E542K
Colorectal Cancer
PIK3CA E542K
Colorectal Cancer
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
PIK3CA E542K
Squamous Cell Carcinoma of Head and Neck
PIK3CA E542K
Squamous Cell Carcinoma of Head and Neck
GDC-0980
Sensitive: C3 – Early Trials
GDC-0980
Sensitive
:
C3
GDC-0980
Sensitive: C3 – Early Trials
GDC-0980
Sensitive
:
C3
PIK3CA E542K
Soft Tissue Sarcoma
PIK3CA E542K
Soft Tissue Sarcoma
trametinib + pazopanib
Sensitive: C4 – Case Studies
trametinib + pazopanib
Sensitive
:
C4
trametinib + pazopanib
Sensitive: C4 – Case Studies
trametinib + pazopanib
Sensitive
:
C4
PIK3CA E542K
Gastric Cancer
PIK3CA E542K
Gastric Cancer
CYH33
Resistant: C4 – Case Studies
CYH33
Resistant
:
C4
CYH33
Resistant: C4 – Case Studies
CYH33
Resistant
:
C4
PIK3CA E542K
Breast Cancer
PIK3CA E542K
Breast Cancer
sirolimus
Sensitive: D – Preclinical
sirolimus
Sensitive
:
D
sirolimus
Sensitive: D – Preclinical
sirolimus
Sensitive
:
D
PIK3CA E542K
Squamous Cell Carcinoma of Head and Neck
PIK3CA E542K
Squamous Cell Carcinoma of Head and Neck
GDC-0032
Sensitive: D – Preclinical
GDC-0032
Sensitive
:
D
GDC-0032
Sensitive: D – Preclinical
GDC-0032
Sensitive
:
D
PIK3CA E542K
Squamous Cell Carcinoma of Head and Neck
PIK3CA E542K
Squamous Cell Carcinoma of Head and Neck
RTB101
Sensitive: D – Preclinical
RTB101
Sensitive
:
D
RTB101
Sensitive: D – Preclinical
RTB101
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login